Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001918828 | SCV002186506 | uncertain significance | not provided | 2022-10-24 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 4671 of the USH2A protein (p.Glu4671Lys). This variant is present in population databases (rs769560933, gnomAD 0.05%). This missense change has been observed in individual(s) with USH2A-related conditions (Invitae). ClinVar contains an entry for this variant (Variation ID: 1411437). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt USH2A protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Dept Of Ophthalmology, |
RCV003888906 | SCV004707223 | uncertain significance | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Ambry Genetics | RCV004681315 | SCV005181333 | uncertain significance | Inborn genetic diseases | 2024-03-18 | criteria provided, single submitter | clinical testing | The c.14011G>A (p.E4671K) alteration is located in exon 64 (coding exon 63) of the USH2A gene. This alteration results from a G to A substitution at nucleotide position 14011, causing the glutamic acid (E) at amino acid position 4671 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |